Difference between revisions of "RhoA"
(New page: {{Subst:infobox}}) |
m |
||
(10 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
− | |||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
− | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
− | | align="center" colspan="2" bgcolor="#ffffff" | [[Image: | + | | align="center" colspan="2" bgcolor="#ffffff" | [[Image:RhoA.JPG|200px|{{PAGENAME}}]] |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
Line 12: | Line 11: | ||
|- | |- | ||
| Determination type | | Determination type | ||
− | | In situ | + | | In situ/In vitro |
|- | |- | ||
| Source | | Source | ||
Line 21: | Line 20: | ||
|- | |- | ||
| Swissprot ID | | Swissprot ID | ||
− | | [http://au.expasy.org/uniprot/ | + | | [http://au.expasy.org/uniprot/P61586 P61586 ] |
|- | |- | ||
| Reactive glutamines | | Reactive glutamines | ||
− | | [[ | + | | [[TG2 reactive residues (RhoA)|Q52, Q63, Q136]] |
|- | |- | ||
| Reactive lysines | | Reactive lysines | ||
− | | | + | | - |
|- | |- | ||
| Substrate sequence | | Substrate sequence | ||
− | | | + | | EVDGK''Q''VELAL |
+ | |||
+ | WDTAG''Q''EDYDR | ||
+ | |||
+ | LAKMK''Q''EPVKP | ||
|- | |- | ||
| Structure | | Structure | ||
− | | [http://www.rcsb.org/pdb/explore/explore.do?structureId= | + | | [http://www.rcsb.org/pdb/explore/explore.do?structureId=1A2B 1A2B] |
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
− | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/ | + | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1a2b.pdf ASAView] pdf |
+ | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1a2b.txt ASAView] txt | ||
|- | |- | ||
| Disorder prediction | | Disorder prediction | ||
Line 42: | Line 46: | ||
|- | |- | ||
| Reference | | Reference | ||
− | | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids= | + | | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=9593707&dopt=Abstract PMID:9593707] |
|- | |- | ||
| Notes | | Notes | ||
− | | | + | | Q63 is deamidated/transamidated by TG2 |
+ | |||
+ | The transamidated protein has increased binding affinity to ROCK-2. | ||
+ | |||
+ | The deamidated form (by cytotoxic dermonecrotizing factor or BTX) has decreased GTPase activity. | ||
+ | |- | ||
+ | |Video | ||
+ | |{{#ev:dailymotion|19dSThNNq2NLtkXZ8|300}} | ||
|- | |- | ||
− | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
+ | [[Category:Deamidase|*]] |
Latest revision as of 11:54, 10 March 2015
RhoA | |
---|---|
Substrate peptide name | RhoA |
Synonyms | - |
Determination type | In situ/In vitro |
Source | Homo sapiens |
Subcellular localization | Cytoskeleton |
Swissprot ID | P61586 |
Reactive glutamines | Q52, Q63, Q136 |
Reactive lysines | - |
Substrate sequence | EVDGKQVELAL
WDTAGQEDYDR LAKMKQEPVKP |
Structure | 1A2B |
Surface accessibility | ASAView pdf
ASAView txt |
Disorder prediction | IUPred |
Reference | PMID:9593707 |
Notes | Q63 is deamidated/transamidated by TG2
The transamidated protein has increased binding affinity to ROCK-2. The deamidated form (by cytotoxic dermonecrotizing factor or BTX) has decreased GTPase activity. |
Video | 19dSThNNq2NLtkXZ8|300}} |